Clinical islet isolation outcomes with a highly purified neutral protease for pancreas dissociation |
| |
Authors: | Doug O'Gorman Tatsuya Kin Rena Pawlick Sharleen Imes Peter A Senior AM James Shapiro |
| |
Affiliation: | 1.Clinical Islet Transplant Program; Department of Transplant Services; Alberta Health Services; Edmonton, AB Canada;2.Department of Surgery; Alberta Diabetes Institute; University of Alberta; Edmonton, AB Canada |
| |
Abstract: | Background: Pancreas dissociation is a critical initial component of the islet isolation procedure and introduces high variability based on factors including the enzyme type, specificity and potency. Product refinement and alterations to the application strategies have improved isolation outcomes over time; however, islet utilization from donor organs remains low. In this study we evaluate a low endotoxin-high activity grade neutral protease in clinical islet isolation.Materials and Methods: The use of a non-collagenolytic enzyme, either thermolysin or high active neutral protease, was randomized in clinical islet isolations to evaluate efficacy. Additionally a retrospective comparison to neutral protease NB was conducted.Results:The thermolysin group had lower trapped islet population and increased purity and post-culture islet mass in comparison to high active grade neutral protease. Comparison of neutral protease NB GMP grade to high active neutral protease displayed no measurable difference in islet mass or viability and transplantation outcomes at 1 mo post-transplant were favorable for both groups.Conclusions: High activity neutral protease can generate clinical grade islets and may prove beneficial to islet function and viability based on a reduced endotoxin load but dosing of neutral protease requires ongoing optimization. |
| |
Keywords: | islet isolation islet transplantation neutral protease thermolysin enzyme dissociation pancreas pancreas dissociation |
|